文献速递膀胱癌与上尿路尿路上皮癌

粪便微生物组特征与肌层浸润性膀胱癌患者对新辅助帕博利珠单抗治疗反应相关

Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol · 2024-01-05

本研究分析PURE-01临床试验(NCT02736266)中42例肌层浸润性膀胱癌患者接受帕博利珠单抗治疗前的粪便微生物组,其中23例达病理缓解;并利用MB49-Luc原位膀胱癌动物模型验证。结果显示应答者与非应答者存在16个细菌分类群富集差异,Sutterella属在应答者中富集,Ruminococcus bromii在非应答者中富集,动物模型亦观察到R. bromii对anti-PD-1抗体活性的负面影响,作者指出需进一步研究外部验证。

要点

  • 42例患者中23例达病理缓解,应答者与非应答者存在16个细菌分类群富集差异。
  • Sutterella属在应答者中富集,Ruminococcus bromii在非应答者中富集。
  • 动物模型观察到R. bromii对anti-PD-1抗体活性及生存的负面影响,作者指出需进一步研究验证。

核心结论

  • 新辅助帕博利珠单抗治疗前粪便中不同细菌分类群与治疗反应与否相关。
  • Sutterella属在应答者中富集,Ruminococcus bromii在非应答者中富集。
  • 动物模型提供R. bromii对免疫治疗反应负面作用的实验数据。
  • 作者指出需进一步研究外部验证这些发现并提供宿主-病原相互作用的机制见解。

研究设计与样本

  • 分析PURE-01临床试验(NCT02736266)中42例肌层浸润性膀胱癌患者帕博利珠单抗治疗前的粪便微生物组,其中23例达病理缓解。
  • 采用MB49-Luc原位膀胱癌动物模型,以anti-PD-1抗体或对照同型抗体处理,验证部分人体数据发现。
  • 使用线性判别分析效应量和线性模型识别应答者或非应答者中富集的细菌分类群。
  • 对识别出的分类群检测其与无事件生存(EFS)的关联。
  • 临床前模型以肿瘤接种后31天生存作为研究终点。

主要发现

  • 应答者与非应答者之间在16个细菌分类群的富集上存在差异。
  • Sutterella属在应答者中富集,Ruminococcus bromii在非应答者中富集。
  • 临床前模型亦观察到R. bromii对anti-PD-1抗体活性的负面影响。
  • EFS与临床前模型生存分析显示R. bromii的负面作用。

临床怎么用

  • 作者指出需进一步研究确认当前发现并检验这些细菌作为免疫治疗反应预测标志物的效用。

局限性

  • 作者指出需进一步研究外部验证这些发现并提供宿主-病原相互作用的机制见解。
  • 作者指出需进一步研究确认当前发现并检验这些细菌作为免疫治疗反应预测标志物的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neoadjuvant pembrolizumab has been shown to be a valid treatment for patients affected by muscle-invasive bladder cancer (MIBC), as demonstrated in the PURE-01 clinical trial (NCT02736266). Among the tumor-extrinsic factors influencing immunotherapy efficacy, extensive data highlighted that the microbiome is a central player in immune-mediated anticancer activity. This report aimed to investigate the composition and role of stool microbiome in patients enrolled in the PURE-01 clinical trial. An orthotopic animal model of bladder cancer (MB49-Luc) was used to support some of the findings from human data. An analysis of stool microbiome before pembrolizumab was conducted for 42 patients, of whom 23 showed a pathologic response. The information in the preclinical model of orthotopic bladder cancer treated with anti-PD-1 antibody or control isotype was validated. Linear discriminant analysis effect size and linear models were used to identify the bacterial taxa enriched in either responders or nonresponders. The identified taxa were also tested for their association with event-free survival (EFS). Survival at 31 d after tumor instillation was used as the study endpoint in the preclinical model. Responders and nonresponders emerged to differ in terms of enrichment for 16 bacterial taxa. Of these, the genus Sutterella was enriched in responders, while the species Ruminococcus bromii was enriched in nonresponders. The negative impact of R. bromii on anti-PD-1 antibody activity was also observed in the preclinical model. EFS and survival of the preclinical model showed a negative role of R. bromii. We found different stool bacterial taxa associated with the response or lack of response to neoadjuvant pembrolizumab. Moreover, we provided experimental data about the negative role of R. bromii on immunotherapy response. Further studies are needed to externally validate our findings and provide mechanistic insights about the host-pathogen interactions in MIBC. PATIENT SUMMARY: Using prepembrolizumab stool samples collected from patients enrolled in the PURE-01 clinical trials, we identified some bacterial taxa that were enriched in patients who either responded or did not respond to immunotherapy. Using an animal model of bladder cancer, we gathered further evidence of the negative impact of the Ruminococcus bromii on immunotherapy efficacy. Further studies are needed to confirm the current findings and test the utility of these bacteria as predictive markers of immunotherapy response.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Pederzoli F, Riba M, Venegoni C, et al. Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer. Eur Urol. 2024. PMID: 38184414. doi:10.1016/j.eururo.2023.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。